エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 06, 2025 |
REVELATION BIOSCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-39603 |
84-3898466 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
4660 La Jolla Village Drive Suite 100 |
|
|||
San Diego, California |
|
92122 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: (650) 800-3717 |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common stock, par value $0.001 per share |
|
REVB |
|
The Nasdaq Stock Market LLC |
Redeemable warrants, each exercisable for a 1/16,800th share of common stock at an exercise price of $193,200.00 per share |
|
REVBW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 6, 2025, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and twelve months ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1.
The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
||
|
|
|
Exhibit No. |
|
Description |
|
||
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
REVELATION BIOSCIENCES, INC. |
|
|
|
|
Date: |
March 6, 2025 |
By: |
/s/ Chester S. Zygmont, III |
|
|
|
Chester S. Zygmont, III |
Exhibit 99.1
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
San Diego, CA – March 6, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results.
Corporate Highlights
“We made significant progress at the end of last year and hope to continue that pace in 2025.” said James Rolke, Chief Executive Officer of Revelation. “Now that the Phase 1b PRIME clinical study is up and running we anticipate the completion of enrollment and more importantly topline data mid-year.”
Results of Operations
As of December 31, 2024, Revelation had $6.5 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The decrease in cash and cash equivalents was primarily due to cash used for operating activities, in large part the LifeSci Capital LLC judgment and payments to other SPAC IPO bankers, which the Company received releases for, offset by net cash received from financing activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations into 2025.
Revelation’s net cash used for operating activities for the twelve months ended December 31, 2024 was $18.3 million compared to net cash used for operating activities of $7.3 million for the same period in 2023. Revelation’s net loss for the three months ended December 31, 2024 was $1.7 million, or $4.98 basic and diluted net loss per share compared to a net loss of $2.2 million, or $133.64 basic and diluted net loss per share for the same period in 2023. Revelation’s net loss for the twelve months ended December 31, 2024 was $15.0 million, or $87.68 basic and diluted net loss per share compared to a net loss of $0.1 million, or $8.44 basic and diluted net loss per share for the same period in 2023.
About Gemini
Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner. Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.
Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program). In addition, Gemini may be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program).
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
605,504 |
|
|
$ |
1,059,984 |
|
|
$ |
3,548,996 |
|
|
$ |
4,145,902 |
|
General and administrative |
|
|
1,148,384 |
|
|
|
1,265,906 |
|
|
|
4,426,113 |
|
|
|
4,510,762 |
|
Total operating expenses |
|
|
1,753,888 |
|
|
|
2,325,890 |
|
|
|
7,975,109 |
|
|
|
8,656,664 |
|
Loss from operations |
|
|
(1,753,888 |
) |
|
|
(2,325,890 |
) |
|
|
(7,975,109 |
) |
|
|
(8,656,664 |
) |
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in fair value of warrant liability |
|
|
2,557 |
|
|
|
68,202 |
|
|
|
81,441 |
|
|
|
8,328,937 |
|
Other (expense) income, net |
|
|
25,612 |
|
|
|
54,785 |
|
|
|
(7,144,868 |
) |
|
|
207,473 |
|
Total other (expense) income, net |
|
|
28,169 |
|
|
|
122,987 |
|
|
|
(7,063,427 |
) |
|
|
8,536,410 |
|
Net loss |
|
$ |
(1,725,719 |
) |
|
$ |
(2,202,903 |
) |
|
$ |
(15,038,536 |
) |
|
$ |
(120,254 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share, basic and diluted |
|
$ |
(4.98 |
) |
|
$ |
(133.64 |
) |
|
$ |
(87.68 |
) |
|
$ |
(8.44 |
) |
Weighted-average shares used to compute net loss per share, basic and diluted |
|
|
346,504 |
|
|
|
16,484 |
|
|
|
171,510 |
|
|
|
14,246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets
|
|
December 31, |
|
|
December 31, |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
6,499,018 |
|
|
$ |
11,991,701 |
|
Deferred offering costs |
|
|
— |
|
|
|
71,133 |
|
Prepaid expenses and other current assets |
|
|
66,699 |
|
|
|
84,691 |
|
Total current assets |
|
|
6,565,717 |
|
|
|
12,147,525 |
|
Property and equipment, net |
|
|
56,332 |
|
|
|
65,084 |
|
Total assets |
|
$ |
6,622,049 |
|
|
$ |
12,212,609 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
783,621 |
|
|
$ |
1,359,898 |
|
Accrued expenses |
|
|
1,127,800 |
|
|
|
1,152,460 |
|
Deferred underwriting commissions |
|
|
— |
|
|
|
2,911,260 |
|
Warrant liability |
|
|
2,246 |
|
|
|
141,276 |
|
Total current liabilities |
|
|
1,913,667 |
|
|
|
5,564,894 |
|
Total liabilities |
|
|
1,913,667 |
|
|
|
5,564,894 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023 and 522,223 and 16,484 issued and outstanding at December 31, 2024 and December 31, 2023, respectively |
|
|
522 |
|
|
|
16 |
|
Additional paid-in-capital |
|
|
45,213,498 |
|
|
|
32,114,801 |
|
Accumulated deficit |
|
|
(40,505,638 |
) |
|
|
(25,467,102 |
) |
Total stockholders’ equity |
|
|
4,708,382 |
|
|
|
6,647,715 |
|
Total liabilities and stockholders’ equity |
|
$ |
6,622,049 |
|
|
$ |
12,212,609 |
|
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester S. Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com